<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04356664</url>
  </required_header>
  <id_info>
    <org_study_id>2019_0012</org_study_id>
    <nct_id>NCT04356664</nct_id>
  </id_info>
  <brief_title>Benefit of GnRH Agonist Before Frozen Embryo Transfer in Patients With Endometriosis and/or Adenomyosis</brief_title>
  <acronym>DECATEC</acronym>
  <official_title>Benefit of Gonadotropin-releasing Hormone (GnRH) Agonist Before Frozen Embryo Transfer in Patients With Endometriosis and / or Adenomyosis: Randomized Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hopital Foch</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hopital Foch</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Women suffering from endometriosis and/or adenomyosis may also suffer from infertility. GnRH&#xD;
      agonist injection could improve implantation and therefore increase the pregnancy rate in&#xD;
      these patients. This study was designed to evaluate effects of the additional of GnRH agonist&#xD;
      (single or 2 doses) to the routine oestrogens and progestins use as support before Frozen&#xD;
      Embryon Transfer as compared to oestrogens and progestins only.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endometriosis reveals the presence of glands or endometrial stroma outside the uterus,&#xD;
      responsible for pain and infertility. Adenomyosis illustrates an invagination of endometrial&#xD;
      islets within the myometrium, leading to a disturbance of its contractile activity, also&#xD;
      potentiated by local hyperestrogenism.&#xD;
&#xD;
      These two pathologies are often associated, and express an alteration of the eutopic&#xD;
      endometrium by pro-inflammatory markers responsible for a lower implantation rate.&#xD;
&#xD;
      GnRH agonists are known to decrease these pro-inflammatory markers (cytochrome P450 and Cox 2&#xD;
      aromatase) in the eutopic endometrium of women with endometriosis or adenomyosis.&#xD;
&#xD;
      Patients will received 1 or 2 injection of GnRH delay agonist (Decapeptyl 3mg) approximately&#xD;
      1 month before the frozen embryo transfer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 18, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical pregnancy rate in both groups at last visit ultrasound</measure>
    <time_frame>3 months after frozen embryon transfer</time_frame>
    <description>Clinical pregnancy will be defined by any cardiac activity detected during the ultrasound performed at the last visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Successful implantation rate on the number of patients included</measure>
    <time_frame>3 months after frozen embryon transfer</time_frame>
    <description>The implantation rate will be evaluated by the number of successful implantations out of the total number of attempts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of miscarriages on the number of patients included</measure>
    <time_frame>3 months after frozen embryon transfer</time_frame>
    <description>The miscarriage rate will be determined by the number of effective miscarriages over the number of successful implantations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects related to treatment with Decapeptyl 3 mg</measure>
    <time_frame>15 months</time_frame>
    <description>Collection of side effects related to treatment with Decapeptyl 3 mg</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Endometriosis</condition>
  <condition>Adenomyosis</condition>
  <condition>Infertility, Female</condition>
  <arm_group>
    <arm_group_label>Frozen embryo transfer with Hormonal Replacement Therapy (HRT)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patient will received usual Hormonal Replacement Therapy for a Frozen embryo transfer composed of estrogens and progestins.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Frozen embryo transfer with HRT and GnRH agonist</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient will received 1 or 2 injection of GnRH agonist priori to usual Hormonal Replacement Therapy for a Frozen embryo transfer composed of estrogens and progestins.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GnRH agonist</intervention_name>
    <description>One or two intramuscular injections of Decapeptyl 3 mg</description>
    <arm_group_label>Frozen embryo transfer with HRT and GnRH agonist</arm_group_label>
    <other_name>Decapeptyl 3 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women aged 18 to 36 years (women ≥18 years to &lt;36 years) with endometriosis and / or&#xD;
             adenomyosis&#xD;
&#xD;
          -  Having benefited from In vitro fertilisation /intracytoplasmic micro-injection with&#xD;
             freeze all and for whom the frozen embryon transfer of a blastocyst is planned&#xD;
&#xD;
          -  A normal uterine cavity&#xD;
&#xD;
          -  An MRI showing endometriosis and / or adenomyosis during the inclusion visit&#xD;
&#xD;
          -  Having signed a consent form&#xD;
&#xD;
          -  Being affiliated to a Health Insurance Plan.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient aged &lt;18 years and ≥ 36 years&#xD;
&#xD;
          -  BMI&gt; 35&#xD;
&#xD;
          -  History of implantation failures (≥ 2)&#xD;
&#xD;
          -  Endometrial alterations: synechiae, polyps, myomas, hyperplasia, hematometra&#xD;
&#xD;
          -  known hydrosalpinx uni or bilateral&#xD;
&#xD;
          -  MRI showing no endometriosis or adenomyosis&#xD;
&#xD;
          -  Hypersensitivity to GnRH, GnRH analogues, or any of the excipients of Decapeptyl 3 mg&#xD;
&#xD;
          -  Known hypersensitivity to estradiol&#xD;
&#xD;
          -  Known hypersensitivity to progesterone&#xD;
&#xD;
          -  Known hypersensitivity to acetylsalicylic acid or other nonsteroidal anti-inflammatory&#xD;
             drugs&#xD;
&#xD;
          -  Known hypersensitivity to folic acid&#xD;
&#xD;
          -  Known hypersensitivity to cefixime or an antibiotic in the cephalosporin group&#xD;
&#xD;
          -  Known hypersensitivity to levofloxacin or any other quinolone&#xD;
&#xD;
          -  History of tendinopathies related to the administration of fluoroquinolones&#xD;
&#xD;
          -  Epilepsy&#xD;
&#xD;
          -  Hypersensitivity to contrast agents for MRI&#xD;
&#xD;
          -  Known or suspected breast cancer or history of breast cancer&#xD;
&#xD;
          -  Known or suspected genital tract cancer or history of genital cancer&#xD;
&#xD;
          -  known or suspected estrogen-dependent malignant neoplasms&#xD;
&#xD;
          -  Undiagnosed genital haemorrhage&#xD;
&#xD;
          -  Untreated endometrial hyperplasia&#xD;
&#xD;
          -  History of idiopathic venous thrombo-embolic accident or evolving venous&#xD;
             thrombo-embolic event (deep vein thrombosis, pulmonary embolism)&#xD;
&#xD;
          -  Recent or evolving arterial thromboembolic stroke (eg angina, myocardial infarction)&#xD;
&#xD;
          -  Acute liver disease or history of liver disease, until hepatic tests are normalized&#xD;
&#xD;
          -  Severe renal insufficiency&#xD;
&#xD;
          -  Severe, uncontrolled heart failure&#xD;
&#xD;
          -  Evolutionary gastroduodenal ulcer&#xD;
&#xD;
          -  History of asthma caused by the administration of salicylates or substances of similar&#xD;
             activity, especially nonsteroidal anti-inflammatory drugs&#xD;
&#xD;
          -  GnRH Agonist Decapeptyl administered within 6 months prior to transfer&#xD;
&#xD;
          -  To be deprived of liberty or under guardianship&#xD;
&#xD;
          -  Pregnancy and breast feeding.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Treatment of female infertility</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>36 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Marc Ayoubi, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Foch</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul Pirtea, Dr</last_name>
    <role>Study Director</role>
    <affiliation>Hopital Foch</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elisabeth Hulier-Ammar, Dr</last_name>
    <phone>0033146251175</phone>
    <phone_ext>+33</phone_ext>
    <email>e.hulier-ammar@hopital-foch.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hopital Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92150</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Pirtea</last_name>
      <phone>+331 46 25 35 20</phone>
      <email>p.pirtea@hopital-foch.com</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 20, 2020</study_first_submitted>
  <study_first_submitted_qc>April 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2020</study_first_posted>
  <last_update_submitted>June 15, 2021</last_update_submitted>
  <last_update_submitted_qc>June 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Endometriosis</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
    <mesh_term>Adenomyosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triptorelin Pamoate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

